KR102696347B1 - 결정성 양진의 치료법 - Google Patents

결정성 양진의 치료법 Download PDF

Info

Publication number
KR102696347B1
KR102696347B1 KR1020197011730A KR20197011730A KR102696347B1 KR 102696347 B1 KR102696347 B1 KR 102696347B1 KR 1020197011730 A KR1020197011730 A KR 1020197011730A KR 20197011730 A KR20197011730 A KR 20197011730A KR 102696347 B1 KR102696347 B1 KR 102696347B1
Authority
KR
South Korea
Prior art keywords
nalbuphine
delete delete
treatment
delivery system
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197011730A
Other languages
English (en)
Korean (ko)
Other versions
KR20190073385A (ko
Inventor
토마스 시아시아
제니퍼 굿
아말 훼
Original Assignee
트레비 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트레비 테라퓨틱스, 인코포레이티드 filed Critical 트레비 테라퓨틱스, 인코포레이티드
Publication of KR20190073385A publication Critical patent/KR20190073385A/ko
Application granted granted Critical
Publication of KR102696347B1 publication Critical patent/KR102696347B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020197011730A 2016-10-25 2017-10-25 결정성 양진의 치료법 Active KR102696347B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662412578P 2016-10-25 2016-10-25
US62/412,578 2016-10-25
PCT/US2017/058294 WO2018081273A1 (en) 2016-10-25 2017-10-25 Treatment of prurigo nodularis

Publications (2)

Publication Number Publication Date
KR20190073385A KR20190073385A (ko) 2019-06-26
KR102696347B1 true KR102696347B1 (ko) 2024-08-19

Family

ID=62025443

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011730A Active KR102696347B1 (ko) 2016-10-25 2017-10-25 결정성 양진의 치료법

Country Status (11)

Country Link
US (3) US20180125840A1 (https=)
EP (1) EP3532061A4 (https=)
JP (2) JP2019532112A (https=)
KR (1) KR102696347B1 (https=)
CN (1) CN109862895A (https=)
AU (1) AU2017350852A1 (https=)
BR (1) BR112019008241A2 (https=)
CA (1) CA3038544A1 (https=)
MX (1) MX2019004804A (https=)
NZ (1) NZ751972A (https=)
WO (1) WO2018081273A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019301134A1 (en) * 2018-07-11 2021-01-21 Trevi Therapeutics, Inc. Treatment of the pruritic symptoms of liver disease
JP2021531299A (ja) 2018-07-23 2021-11-18 トレビ セラピューティクス インコーポレイテッド 慢性咳嗽、息切れ、及び呼吸困難の治療
KR20220127849A (ko) * 2020-01-10 2022-09-20 트레비 테라퓨틱스, 인코포레이티드 날부핀의 투여 방법
US12508259B2 (en) 2022-02-01 2025-12-30 HUMANWELL PHARMACEUTICAL US, Inc. Pharmaceutical formulations containing Nalbuphine

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359789A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003261298A1 (en) * 2002-08-02 2004-02-23 Penwest Pharmaceuticals Company Sustained release formulations of metformin
JP2005162736A (ja) * 2003-11-10 2005-06-23 Astellas Pharma Inc 徐放性医薬組成物
US20050169991A1 (en) * 2003-12-12 2005-08-04 Penwest Pharmaceuticals Co. Sustained release torsemide dosage forms
HUE053838T2 (hu) * 2005-08-24 2021-07-28 Endo Pharmaceuticals Inc Nyújtott felszabadulású nabulfin-készítmények
EP2240110A4 (en) * 2008-01-29 2015-07-01 Superdimension Ltd TARGET IDENTIFICATION INSTRUMENT FOR LOCALIZATION IN THE BODY
US8987289B2 (en) * 2012-12-14 2015-03-24 Trevi Therapeutics, Inc. Methods for treating pruritus
ES2984559T3 (es) * 2012-12-14 2024-10-29 Trevi Therapeutics Inc Métodos de tratamiento del prurito
WO2017120468A1 (en) * 2016-01-06 2017-07-13 Trevi Therapeutics, Inc. Therapeutic use of nalbuphine without aquaretic effects
CN105560202B (zh) * 2016-03-11 2019-05-24 广州玻思韬控释药业有限公司 一种盐酸纳布啡凝胶骨架缓释片的制备方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150359789A1 (en) * 2014-06-13 2015-12-17 Trevi Therapeutics, Inc. Methods for treating pruritus

Also Published As

Publication number Publication date
BR112019008241A2 (pt) 2019-07-16
EP3532061A4 (en) 2020-07-08
CA3038544A1 (en) 2018-05-03
MX2019004804A (es) 2019-08-22
US20230338367A1 (en) 2023-10-26
CN109862895A (zh) 2019-06-07
EP3532061A1 (en) 2019-09-04
NZ751972A (en) 2022-12-23
US20220347171A1 (en) 2022-11-03
JP2022191405A (ja) 2022-12-27
KR20190073385A (ko) 2019-06-26
WO2018081273A1 (en) 2018-05-03
AU2017350852A1 (en) 2019-04-11
US20180125840A1 (en) 2018-05-10
JP2019532112A (ja) 2019-11-07

Similar Documents

Publication Publication Date Title
AU2018214098B2 (en) Methods for treating pruritus
US20230338367A1 (en) Treatment of prurigo nodularis
US20250032480A1 (en) Methods for treating pruritus
US8987289B2 (en) Methods for treating pruritus
US20190099416A1 (en) Methods for treating pruritus
JP2022081640A (ja) 尿毒症性掻痒の治療法
US20170216277A1 (en) Therapeutic use of nalbuphine without aquaretic effects
AU2021206252B2 (en) Methods of administering nalbuphine
CA3105680A1 (en) Treatment of the pruritic symptoms of liver disease
HK40003409A (en) Treatment of prurigo nodularis
HK40013011A (en) Methods for treating pruritus

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190423

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201023

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230303

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230905

Patent event code: PE09021S02D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240521

Patent event code: PE09021S02D

Comment text: Final Notice of Reason for Refusal

Patent event date: 20230905

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240813

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240814

End annual number: 3

Start annual number: 1

PG1601 Publication of registration